First-cycle β-hCG dynamics predict single-agent chemoresistance in low-risk gestational trophoblastic neoplasia

BACKGROUND: This study aimed to introduce a first-cycle β-hCG response marker for predicting first-line single-agent chemoresistance in low-risk gestational trophoblastic neoplasia (GTN). METHODS: This retrospective study included 299 patients. Patients were randomly assigned to a development cohort (n = 198) and internal validation cohort (n = 101). The primary exposure was the C2/C1 β-hCG ratio, defined as the serum β-hCG level before cycle 2 divided by the level before cycle 1. Restricted cubic spline and receiver operating characteristic analyses were used to derive the optimal threshold. Three models were evaluated: a FIGO-only model, a baseline clinical model, and a first-cycle dynamic model incorporating the C2/C1 ratio. RESULTS: First-line single-agent chemoresistance occurred in 45 patients in the development cohort and 23 in the internal validation cohort. The optimal C2/C1 β-hCG threshold was 0.38. Patients with a poor first-cycle response had higher chemoresistance rates than favorable responders in both the development cohort (43.8% vs. 8.5%) and internal validation cohort (44.7% vs. 9.5%). The dynamic model showed superior discrimination compared with the baseline clinical model, with AUCs of 0.867 in the development cohort and 0.844 in the internal validation cohort. Addition of the C2/C1 ratio improved calibration, reduced Brier scores, and yielded significant reclassification improvement. Poor responders required more cycles to β-hCG normalization, more total chemotherapy cycles, and more frequent second-line or multi-agent therapy. CONCLUSIONS: The first-cycle C2/C1 β-hCG ratio showed potential for predicting first-line single-agent chemoresistance in low-risk GTN. A threshold of 0.38 may help identify patients requiring closer monitoring, but requires prospective multicenter validation.

Authors

Institutions

Publication Details

Journal
Gynecologic Oncology
Published
2026-11-14
DOI
https://doi.org/10.1016/j.ygyno.2026.11.006
Primary Topic
Gestational Trophoblastic Disease Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

First-cycle β-hCG dynamics predict single-agent chemoresistance in low-risk gestational trophoblastic neoplasia

车艳辞, Xinyue Luan, Yan Wang, Xiao Li et al.
1 links
Gynecologic Oncology
Gestational Trophoblastic Disease Studies
article

First-cycle β-hCG dynamics predict single-agent chemoresistance in low-risk gestational trophoblastic neoplasia

车艳辞, Xinyue Luan, Yan Wang, Xiao Li, Yan Kong, Tian Tian, Zhumei Cui
article en

Abstract

BACKGROUND: This study aimed to introduce a first-cycle β-hCG response marker for predicting first-line single-agent chemoresistance in low-risk gestational trophoblastic neoplasia (GTN). METHODS: This retrospective study included 299 patients. Patients were randomly assigned to a development cohort (n = 198) and internal validation cohort (n = 101). The primary exposure was the C2/C1 β-hCG ratio, defined as the serum β-hCG level before cycle 2 divided by the level before cycle 1. Restricted cubic spline and receiver operating characteristic analyses were used to derive the optimal threshold. Three models were evaluated: a FIGO-only model, a baseline clinical model, and a first-cycle dynamic model incorporating the C2/C1 ratio. RESULTS: First-line single-agent chemoresistance occurred in 45 patients in the development cohort and 23 in the internal validation cohort. The optimal C2/C1 β-hCG threshold was 0.38. Patients with a poor first-cycle response had higher chemoresistance rates than favorable responders in both the development cohort (43.8% vs. 8.5%) and internal validation cohort (44.7% vs. 9.5%). The dynamic model showed superior discrimination compared with the baseline clinical model, with AUCs of 0.867 in the development cohort and 0.844 in the internal validation cohort. Addition of the C2/C1 ratio improved calibration, reduced Brier scores, and yielded significant reclassification improvement. Poor responders required more cycles to β-hCG normalization, more total chemotherapy cycles, and more frequent second-line or multi-agent therapy. CONCLUSIONS: The first-cycle C2/C1 β-hCG ratio showed potential for predicting first-line single-agent chemoresistance in low-risk GTN. A threshold of 0.38 may help identify patients requiring closer monitoring, but requires prospective multicenter validation.

Gynecologic OncologyVol. 215
Affiliated Hospital of Qingdao University (CN), Women's Hospital, School of Medicine, Zhejiang University (CN), Zhejiang University (CN)
Ministry of Science and Technology of the People's Republic of China
Good health and well-being
Gestational Trophoblastic Disease Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon